(Q40804196)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

review article

1 reference

title

Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

author name string

P Chanson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

J Timsit

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

publication date

1 November 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

28 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

page(s)

375-391

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8287633%20AND%20SRC:MED&resulttype=core&format=json

Long-term efficacy and tolerability of octreotide treatment in acromegaly

28 October 2019

cites work

1 reference

12 December 2020

Resistance to somatostatin (SRIH) analog therapy in acromegaly. Re-evaluation of the correlation between the SRIH receptor status of the pituitary tumor and the in vivo inhibition of GH secretion in response to SRIH analog

1 reference

12 December 2020

Gallstones during octreotide therapy

1 reference

12 December 2020

Conventional Supervoltage Irradiation Is an Effective Treatment for Acromegaly

1 reference

12 December 2020

Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization

1 reference

12 December 2020

Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995

1 reference

12 December 2020

A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly

1 reference

12 December 2020

Effects of antibodies against octreotide in two patients with acromegaly

1 reference

12 December 2020

Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly

1 reference

12 December 2020

Biologic and immunologic activities and applications of somatostatin analogs

1 reference

12 December 2020

Clinical review 22: Therapeutic options in acromegaly

1 reference

12 December 2020

Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients

1 reference

12 December 2020

Acromegaly. Diagnosis and therapy.

1 reference

12 December 2020

Continuous infusion of octreotide in acromegaly

1 reference

12 December 2020

Prevalence of gastritis in patients with acromegaly: untreated and during treatment with octreotide

1 reference

12 December 2020

The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study

1 reference

12 December 2020

Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration

1 reference

12 December 2020

Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly

1 reference

12 December 2020

Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients

1 reference

12 December 2020

Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia

1 reference

12 December 2020

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

1 reference

12 December 2020

Oral absorption of the somatostatin analogue SMS 201-995: theoretical and practical implications

1 reference

12 December 2020

Disposition of sandostatin, a new synthetic somatostatin analogue, in rats

1 reference

12 December 2020

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

12 December 2020

Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions

1 reference

12 December 2020

Effect of the somatostatin analogue SMS 201-995 on faecal fat excretion in acromegaly

1 reference

12 December 2020

Pharmacodynamic effects of Sandostatin in the gastrointestinal tract

1 reference

12 December 2020

The effect of a long-acting somatostatin analogue (SMS 201-995) on intermediary metabolism and gut hormones after a test meal in normal subjects

1 reference

12 December 2020

Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995).

1 reference

12 December 2020

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

1 reference

12 December 2020

Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue

1 reference

12 December 2020

Prolonged inhibition of meal-stimulated acid secretion and gastrin release following single subcutaneous administration of octreotide (SMS 201-995) in man

1 reference

12 December 2020

Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine

1 reference

12 December 2020

Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly.

1 reference

12 December 2020

Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study.

1 reference

12 December 2020

The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease

1 reference

12 December 2020

Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).

1 reference

12 December 2020

How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors?

1 reference

12 December 2020

Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with sandostatin (SMS 201-995).

1 reference

12 December 2020

The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas

1 reference

12 December 2020

The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors

1 reference

12 December 2020

Acute hepatitis after treatment of acromegaly with octreotide

1 reference

12 December 2020

Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients

1 reference

12 December 2020

Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly

1 reference

12 December 2020

Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients

1 reference

12 December 2020

Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion

1 reference

12 December 2020

The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients

1 reference

12 December 2020

The effect of minisomatostatin on anomalous growth hormone responses in acromegaly

1 reference

12 December 2020

Effect of a long-acting somatostatin analogue (SMS 201-995) on postprandial gastric emptying of 99mTc-tin colloid and mouth-to-caecum transit time in man

1 reference

12 December 2020

The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones

1 reference

12 December 2020

The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas

1 reference

12 December 2020

Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly

1 reference

12 December 2020

Effects of octreotide on lipid metabolism in acromegaly

1 reference

12 December 2020

Comparison of the pharmacokinetics of octreotide injected at two subcutaneous sites

1 reference

12 December 2020

Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety

1 reference

12 December 2020

Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995.

1 reference

12 December 2020

Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients

1 reference

12 December 2020

A prospective examination of octreotide-induced gall-bladder changes in acromegaly

1 reference

12 December 2020

Molecular biology of somatostatin receptors

1 reference

12 December 2020

1 reference

12 December 2020

Enteral absorption of octreotide

1 reference

12 December 2020

Effects of somatostatin and SMS 201-995 on carbohydrate metabolism in normal man

1 reference

12 December 2020

Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly

1 reference

12 December 2020

Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin).

1 reference

12 December 2020

Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects

1 reference

12 December 2020

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

1 reference

12 December 2020

Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration.

1 reference

12 December 2020

Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly

1 reference

12 December 2020

High Density of Somatostatin Receptors in Pituitary Tumors from Acromegalic Patients

1 reference

12 December 2020

Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors

1 reference

12 December 2020

Structure-function relationships of somatostatin analogs

1 reference

12 December 2020

Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide.

1 reference

12 December 2020

Single-dose response study of the somatostatin analogue octreotide in acromegaly

1 reference

12 December 2020

The effect of SMS 201-995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers

1 reference

12 December 2020

Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide

1 reference

12 December 2020

Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma

1 reference

12 December 2020

Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting pituitary adenoma

1 reference

12 December 2020

Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide

1 reference

12 December 2020

Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.

1 reference

12 December 2020

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney

1 reference

12 December 2020

From somatostatin to sandostatin: pharmacodynamics and pharmacokinetics

1 reference

12 December 2020

Acute and long-term effects of SMS 201-995 in acromegaly

1 reference

12 December 2020

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

1 reference

12 December 2020

Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995

1 reference

12 December 2020

Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment

1 reference

12 December 2020

Cardiovascular effects of the somatostatin analog octreotide in acromegaly

1 reference

12 December 2020

Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas

1 reference

12 December 2020

Effects of somatostatin analogue SMS 201-995 in normal man

1 reference

12 December 2020

Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group

1 reference

12 December 2020

The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly

1 reference

12 December 2020

SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years

1 reference

12 December 2020

Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly

1 reference

12 December 2020

Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.

1 reference

12 December 2020

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

1 reference

12 December 2020

Postprandial exocrine pancreatic function during long-term treatment with the somatostatin analogue SMS 201-995 in acromegalic patients

1 reference

12 December 2020

Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy.

1 reference

12 December 2020

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

1 reference

12 December 2020

Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly

1 reference

12 December 2020

Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage

1 reference

12 December 2020

A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs

1 reference

12 December 2020

Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment

1 reference

12 December 2020

Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995.

1 reference

12 December 2020

Pharmacokinetics of SMS 201-995 in healthy subjects

1 reference

12 December 2020

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

1 reference

12 December 2020

Octreotide treatment in acromegaly: a comparison between pen-treated and pump-treated patients in a cross-over study

1 reference

12 December 2020